Page 164 - 2019_01-Haematologica-web

A.P. Kater et al.
18. Rawstron A, Böttcher S, Letestu R, et al.
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual dis- ease monitoring in CLL. Leukemia. 2013;27(1):142.
19. Cairo MS, Bishop M. Tumour lysis syn- drome: new therapeutic strategies and clas- sification. Br J Haematol. 2004;127(1):3-11.
20. Trotti A, Colevas AD, Setser A, et al. CTCAE v3. 0: development of a compre- hensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181.
21. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a ran-
domised, multicentre, open-label phase 3
trial. Lancet. 2015;385(9980):1873-1883. 22. Cheson B, Bennett J, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lym- phocytic leukemia: revised guidelines for diagnosis and treatment. Blood.
1996;87(12): 4990-4997.
23. O’Brien S, Furman RR, Coutre S, et al.
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocyt- ic leukemia: a 5-year experience. Blood. 2018;131(17):1910-1919.
24. Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013;31(5):584.
25. Fink AM, Bahlo J, Robrecht S, et al. Lenalidomide maintenance after first-line
therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017;4(10):e475-e486.
26. Shanafelt TD, Ramsay AG, Zent CS, et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 2013;121(20):4137- 4141.
27. Strati P, Keating MJ, Wierda WG, et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013;122(5):734-737.
28. Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129 (19):2702-2705.
154
haematologica | 2019; 104(1)